Plasma adiponectin levels and hypoxic stress in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2004 - Systemic and metabolic effects from OSA Year: 2004
Serum leptin levels in obese patients with severe obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 332s Year: 2004
BNP or VEGF levels do not predict disease severity in obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2005; 26: Suppl. 49, 40s Year: 2005
Investigation on serum adiponectin levels in patients with obstructive sleep apnea hypopnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 445s Year: 2004
Plasma levels of TNF in obstructive sleep apnea syndrome (OSA) before and after surgical intervention Source: Annual Congress 2012 - Clinical predictors of OSA, adherence to CPAP and psychology Year: 2012
The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 113s Year: 2004
Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 332s Year: 2004
Endothelin-1 levels, respiratory drive and hypercapnic response in obese patients with or without obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2010 - Lung disease and mountain sickness: the importance of ventilatory control Year: 2010
Plasma homocysteine (Hcy) levels in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2007 - Cardiovascular and respiratory control in obstructive sleep apnoea Year: 2007
Plasma orexin-A levels in patients with obstructive sleep apnea syndrome Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Cardiovascular diseases are responsible for increased plasma NT-proBNP level in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA Year: 2012
Comparison of plasma NT-proBNP level in overlap syndrome (obstructive sleep apnoea + chronic obstructive pulmonary disease) and obstructive sleep apnoea (OSA) Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep Year: 2008
Serum leptin levels in obstructive sleep apnoea patients Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Fibrinogen level in patients with severe obstructive sleep apnoea syndrome (OSAS). Effect of n-CPAP therapy Source: Eur Respir J 2001; 18: Suppl. 33, 216s Year: 2001
The effect of theophylline and CPAP on cytokine release in patients with obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2006; 28: Suppl. 50, 216s Year: 2006
Effect of 8 week CPAP therapy on insulin resistance, serum leptin and lipid concentrations among obstructive sleep apnea hypopnea syndrome (OSAS) patients Source: Eur Respir J 2004; 24: Suppl. 48, 330s Year: 2004
PAI-uPA system in patients with obstructive sleep apnea syndrome (OSAS) in CPAP treatment Source: Annual Congress 2012 - Cardiovascular disease and sleep-disordered breathing Year: 2012
Relationship between NT-proBNP plasma level and nocturia in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2007 - Systemic effects of obstructive sleep apnoea Year: 2007
Elevated c-reactive protein in patients with obstructive sleep apnea hypopnea syndrome (OSAH) Source: Annual Congress 2007 - Systemic effects of obstructive sleep apnoea Year: 2007
The impact of obstructive sleep apnea syndrome (SAOS) on serum testosterone level Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing Year: 2009